Australia - Inggris - Department of Health (Therapeutic Goods Administration)

amneal pharma australia pty ltd - simvastatin -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - pravastatin sodium -

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atorvastatin calcium, quantity: 41.36 mg (equivalent: atorvastatin, qty 40 mg) - tablet, film coated - excipient ingredients: hyprolose; hypromellose; lactose monohydrate; magnesium stearate; colloidal anhydrous silica; macrogol 4000; titanium dioxide; pregelatinised maize starch; microcrystalline cellulose; activated attapulgite - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atorvastatin calcium, quantity: 82.72 mg (equivalent: atorvastatin, qty 80 mg) - tablet, film coated - excipient ingredients: magnesium stearate; pregelatinised maize starch; activated attapulgite; hyprolose; colloidal anhydrous silica; lactose monohydrate; hypromellose; microcrystalline cellulose; macrogol 4000; titanium dioxide - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atorvastatin calcium, quantity: 10.34 mg (equivalent: atorvastatin, qty 10 mg) - tablet, film coated - excipient ingredients: hypromellose; macrogol 4000; magnesium stearate; titanium dioxide; lactose monohydrate; colloidal anhydrous silica; hyprolose; microcrystalline cellulose; pregelatinised maize starch; activated attapulgite - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Australia - Inggris - Department of Health (Therapeutic Goods Administration)

generic health pty ltd - atorvastatin calcium, quantity: 20.68 mg (equivalent: atorvastatin, qty 20 mg) - tablet, film coated - excipient ingredients: lactose monohydrate; macrogol 4000; pregelatinised maize starch; activated attapulgite; magnesium stearate; hypromellose; titanium dioxide; microcrystalline cellulose; colloidal anhydrous silica; hyprolose - an adjunct to diet for the treatment of patients with hypercholesterolaemia. prior to initiating therapy with atorvastatin, secondary causes of hypercholesterolaemia (e.g. poorly controlled diabetes mellitus, hypothyroidism, nephrotic syndrome, dysproteinaemias, obstructive liver disease, other drug therapy and alcoholism) should be identified and treated. hypertensive patients with multiple risk factors for chd which may include diabetes, history of stroke or other cerebrovascular disease, peripheral vascular disease or existing asymptomatic chd (see actions, clinical trials, prevention of cardiovascular disease) to reduce the risk of nonfatal mi and nonfatal stroke.,these effects do not replace the need to independently control known causes of cardiovascular mortality and morbidity such as hypertension, diabetes and smoking.

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - simvastatin - oral tablet - 10mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

teva uk ltd - simvastatin - oral tablet - 20mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - simvastatin - oral tablet - 10mg

Inggris - Inggris - MHRA (Medicines & Healthcare Products Regulatory Agency)

actavis uk ltd - simvastatin - oral tablet - 20mg